Company news

Microba Life Sciences Limited news in 2023

Microba Life Sciences Limited's news releases, calls and decks from 2023, newest first.

View company

Successful IBD Phase I Clinical Trial

December 6, 2023

Research Agreement Executed with IFF for Allergy Program

December 3, 2023

Autoimmune Stage 1 Screening Complete with Gingko Bioworks

November 27, 2023

Results of Retail Entitlement Offer

November 19, 2023

Fully Underwritten A$20 million Entitlement Offer

October 22, 2023

Invivo Clinical Acquisition and Capital Raising Presentation

October 18, 2023

Microba to acquire UK microbiome leader Invivo Clinical

October 18, 2023

Q1 FY24 Quarterly Activities Report & Appendix 4C

October 18, 2023

Appendix 4E & Annual Report

August 29, 2023

Q4 FY23 Quarterly Investor Presentation

July 26, 2023

Q4 FY23 Quarterly Activities Report & Appendix 4C

July 26, 2023

First Distribution Agreement Executed with Sonic Healthcare

July 4, 2023

Microba Commences Phase I Clinical Trial for IBD Therapeutic

June 27, 2023

MRFF Grant Awarded to QUT, In Collaboration With Microba

June 27, 2023

Microba receives two AusIndustry Advanced Overseas Findings

June 14, 2023

Q3 FY23 Quarterly Investor Presentation

April 19, 2023

Q3 FY23 Quarterly Activities Report & Appendix 4C

April 19, 2023

SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia

April 12, 2023

Microba Receives Ethics Approval for Phase 1 Clinical Trial

March 29, 2023

SYNLAB Agreements Signed in Turkiye and Czech Republic

March 1, 2023

Microba Launches Next Generation Healthcare Testing

February 27, 2023

H1 FY23 Interim Report

February 22, 2023

US Distribution Agreement Signed with Luminary Health

February 6, 2023

Positive first animal data for Cancer Program

January 31, 2023

Q2 FY23 Quarterly Activities Report & Appendix 4C

January 29, 2023

Calls in 2023

Decks in 2023